– USA, MA – Vor Biopharma (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced the appointments of Bo Cumbo and Dr. Michel Detheux (Ph.D.) to its Board of Directors, effective July 16, 2025.
About Alexander (Bo) Cumbo
Bo Cumbo serves as President and CEO of Solid Biosciences. Before that, he was the founding CEO of AavantiBio, a gene therapy company backed by Bain Capital Life Sciences, Perceptive Advisors, and RA Capital. Bo brings more than 30 years of commercial and executive leadership, including nearly eight years at Sarepta Therapeutics, where he most recently served as EVP and CCO. He played a central role in launching multiple rare disease therapies and building global commercial operations.
Bo Cumbo serves on the boards of Climb Bio and Verve Therapeutics and previously served on the boards of RA Pharma and CSM through successful transactions.
Bo Cumbo earned a Bachelor of Science in Laboratory Technology from Auburn University.
About Dr. Michel Detheux
Dr. Michel Detheux is President and CEO of iTeos Therapeutics, which he co-founded and led from discovery to late-stage clinical development. Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company’s lead anti-TIGIT antibody. Before founding iTeos, Dr. Michel Detheux was a Director at Ludwig Cancer Research and held scientific and business development roles at Euroscreen (now Ogeda). He currently serves as Chairman of the Board at Egle Therapeutics.
Dr. Michel Detheux holds a Ph.D. in Biochemistry and a degree in Bioengineering from Université Catholique de Louvain.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.
For more: https://www.vorbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.